摘要
免疫性血小板减少性紫癜(ITP)是最常见的自身免疫性疾病,是由抗体介导的血小板和巨核细胞-血小板生成受损产生的。ITP是一种排除性诊断。最近ITP的病理生理机制和治疗方法已开始出现。虽然类固醇和静脉注射免疫球蛋白(IVIg)仍然是主要的治疗策略,一组患者最终产生了耐药性,尤其是近十年已经有一些生物治疗方案,如利妥昔单抗。在这篇综述中,我们总结了ITP患者的治疗方案,主要集中在时间和生物制剂的潜在影响。
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
Current Medicinal Chemistry
Title:Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Volume: 22 Issue: 16
Author(s): Melda Comert Ozkan, Fahri Sahin and Guray Saydam
Affiliation:
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
摘要: Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.
Export Options
About this article
Cite this article as:
Melda Comert Ozkan, Fahri Sahin and Guray Saydam , Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150319102830
DOI https://dx.doi.org/10.2174/0929867322666150319102830 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Hypersensitivity Pneumonitis
Current Pediatric Reviews Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design GCPII Variants, Paralogs and Orthologs
Current Medicinal Chemistry Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews 4’-Aminochalcones As Novel Inhibitors of the Chlorinating Activity of Myeloperoxidase
Current Medicinal Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens
Current HIV Research Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis
Current Pharmaceutical Design A Case of Pulmonary Tuberculosis Mimicking as Diffuse Alveolar Hemorrhage: A Case Report
New Emirates Medical Journal Imaging Neuroinflammation in Ischemic Stroke and in the Atherosclerotic Vascular Disease
Current Vascular Pharmacology Are Reactive Oxygen Species Important Mediators of Vascular Dysfunction?
Current Hypertension Reviews In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design